Effect of Intravitreal Injection of Bevacizumab on Acute Central Serous Chorioretinopathy Patients who Visited Feiz Hospital during 2014–2015 Period


Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Aim of this clinical trial is the evaluation of the effect of intravitreal injection of bevacizumab on acute central serous chorioretinopathy (CSC). Materials and Methods: In a nonrandomized clinical trial, 36 CSC eyes (with <1-month disease history) were examined. Initially, all the patients underwent posterior and anterior segment examinations as well as complete eye examination to evaluate the best spectacle-corrected visual acuity (BSCVA). Then, optical coherence tomography was performed to confirm the diagnosis. The patients were divided to the two groups each of 18 subjects, which 18 patients received intravitreal injection of bevacizumab (1.25 mg) and the rest of them did not receive any treatment (control group). The patients were health checked by the end of the 1st and 3rd months. Significance level was considered as P < 0.05. Results: In the BSCVA, no significant difference in visual improvement was observed in baseline vision compared to each other (P = 0.481). There was also no significant difference in the vision of intervention and control groups 1 and 3 months after injection (P = 0.379 and P = 0.557). A significant decrement existed in the intervention group compared with the control group in the maximum central macular thickness at 1 month after injection (P = 0.001); however, the difference was not significant when comparing the two groups at baseline and 3 months after injection (P = 0.925 and P = 0.338). Conclusion: In general, according to the results of this study, intravitreal injection of bevacizumab was not effective in improvement of patients with acute CSC, although it had no side effects.


Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86:].  Back to cited text no. 1
Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD, et al. Apilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246:].  Back to cited text no. 2
Boscia F. When to treat and not to treat patients with central serous retinopathy. Retin Today 2010; 42:32-34.  Back to cited text no. 3
Wei SY, Yang CM. Transpupillary thermotherapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2005; 36:412-5.  Back to cited text no. 4
Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol 2004; 137:1073-80.  Back to cited text no. 5
Ryan SJ. Retina. In: Christina M, editor. Central Serous Chorioretinopathy. 4th ed. China: Elsevier, Mosby; 2006. p. 1135-61.  Back to cited text no. 6
Maia A. A new treatment for chronic central serous retinopathy. Retin Today 2010. Retrieved 2013-08-11. [Last accessed on 2013 Aug 11].  Back to cited text no. 7
Mehany SA, Shawkat AM, Sayed MF, Mourad KM. Role of avastin in management of central serous chorioretinopathy. Saudi J Ophthalmol 2010; 24:69-75.  Back to cited text no. 8
Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Central serous chorioretinopathy: A pathogenetic model. Clin Ophthalmol 2011; 5:239-43.  Back to cited text no. 9
Colucciello M. Central serous retinopathy. Retin Physician 2010. Available from: http://www.retinalphisician.com/article.aspx. [Last accessed on 2012 Jun 01].  Back to cited text no. 10
Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007; 27:943-6.  Back to cited text no. 11
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.e5.  Back to cited text no. 12
Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27:141-9.  Back to cited text no. 13
Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27:419-25.  Back to cited text no. 14
Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996; 114:689-92.  Back to cited text no. 15
Vingrys AJ, Pesudovs K. Localized scotomata detected with temporal modulation perimetry in central serous chorioretinopathy. Aust N Z J Ophthalmol 1999; 27:109-16.  Back to cited text no. 16
Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121:26-34.  Back to cited text no. 17
Prünte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int Ophthalmol 1995; 19:77-82.  Back to cited text no. 18
Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J Ocul Pharmacol Ther 2013; 29:10-3.  Back to cited text no. 19
Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24:155-8.  Back to cited text no. 20
Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: Short-term effect. Ophthalmologica 2009; 223:343-7.  Back to cited text no. 21
Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30:100-6.  Back to cited text no. 22